NO20006008L - Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer - Google Patents

Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer

Info

Publication number
NO20006008L
NO20006008L NO20006008A NO20006008A NO20006008L NO 20006008 L NO20006008 L NO 20006008L NO 20006008 A NO20006008 A NO 20006008A NO 20006008 A NO20006008 A NO 20006008A NO 20006008 L NO20006008 L NO 20006008L
Authority
NO
Norway
Prior art keywords
fatty acid
acid analogues
inflammatory
treatment
autoimmune diseases
Prior art date
Application number
NO20006008A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006008D0 (no
Inventor
Rolf Berge
Paal Aukrust
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Priority to NO20006008A priority Critical patent/NO20006008L/no
Publication of NO20006008D0 publication Critical patent/NO20006008D0/no
Priority to PCT/NO2001/000470 priority patent/WO2002043728A1/en
Priority to RU2003115423/15A priority patent/RU2259823C2/ru
Priority to MXPA03004427A priority patent/MXPA03004427A/es
Priority to KR1020037007097A priority patent/KR100905335B1/ko
Priority to NZ525889A priority patent/NZ525889A/en
Priority to EP01998347A priority patent/EP1351672B1/en
Priority to AU2316202A priority patent/AU2316202A/xx
Priority to AT01998347T priority patent/ATE432071T1/de
Priority to JP2002545699A priority patent/JP4368579B2/ja
Priority to US10/416,378 priority patent/US8088825B2/en
Priority to ES01998347T priority patent/ES2326159T3/es
Priority to DE60138834T priority patent/DE60138834D1/de
Priority to BR0115527-0A priority patent/BR0115527A/pt
Priority to CA2457925A priority patent/CA2457925C/en
Priority to CNB018196969A priority patent/CN1296039C/zh
Priority to AU2002223162A priority patent/AU2002223162B2/en
Publication of NO20006008L publication Critical patent/NO20006008L/no
Priority to NO20032054A priority patent/NO324557B1/no
Priority to ZA200303668A priority patent/ZA200303668B/en
Priority to HK05106536A priority patent/HK1073793A1/xx
Priority to US13/340,157 priority patent/US20120101161A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
NO20006008A 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer NO20006008L (no)

Priority Applications (21)

Application Number Priority Date Filing Date Title
NO20006008A NO20006008L (no) 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
AU2002223162A AU2002223162B2 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
US10/416,378 US8088825B2 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
DE60138834T DE60138834D1 (de) 2000-11-28 2001-11-27 Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen
MXPA03004427A MXPA03004427A (es) 2000-11-28 2001-11-27 Analogos de acido graso para el tratamiento de desordenes inflamatorios y autoinmunes.
KR1020037007097A KR100905335B1 (ko) 2000-11-28 2001-11-27 염증성 및 자가 면역성 장애를 치료하기 위한 지방산 동족체
NZ525889A NZ525889A (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
EP01998347A EP1351672B1 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
AU2316202A AU2316202A (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
AT01998347T ATE432071T1 (de) 2000-11-28 2001-11-27 Fettsäureanaloge zur behandlung von entzündungs- und autoimmunerkrankungen
JP2002545699A JP4368579B2 (ja) 2000-11-28 2001-11-27 炎症障害および自己免疫障害の治療用の脂肪酸アナログ
PCT/NO2001/000470 WO2002043728A1 (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
ES01998347T ES2326159T3 (es) 2000-11-28 2001-11-27 Analogos de acidos grasos para el tratamiento de enfermedades inflamatorias y autoinmunes.
RU2003115423/15A RU2259823C2 (ru) 2000-11-28 2001-11-27 Аналоги жирных кислот для лечения воспалительных и аутоиммунных расстройств
BR0115527-0A BR0115527A (pt) 2000-11-28 2001-11-27 Análogos de ácido graxo para o tratamento de distúrbios imflamatórios e autoimunes
CA2457925A CA2457925C (en) 2000-11-28 2001-11-27 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
CNB018196969A CN1296039C (zh) 2000-11-28 2001-11-27 治疗炎症和自身免疫性疾病的脂肪酸类似物
NO20032054A NO324557B1 (no) 2000-11-28 2003-05-08 Anvendelse av fettsyreanaloger for a hindre og/eller behandle inflammatoriske og/eller autoimmune forstyrrelser.
ZA200303668A ZA200303668B (en) 2000-11-28 2003-05-13 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders.
HK05106536A HK1073793A1 (en) 2000-11-28 2005-08-01 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
US13/340,157 US20120101161A1 (en) 2000-11-28 2011-12-29 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20006008A NO20006008L (no) 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer

Publications (2)

Publication Number Publication Date
NO20006008D0 NO20006008D0 (no) 2000-11-28
NO20006008L true NO20006008L (no) 2002-05-29

Family

ID=19911849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006008A NO20006008L (no) 2000-11-28 2000-11-28 Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer

Country Status (18)

Country Link
US (2) US8088825B2 (xx)
EP (1) EP1351672B1 (xx)
JP (1) JP4368579B2 (xx)
KR (1) KR100905335B1 (xx)
CN (1) CN1296039C (xx)
AT (1) ATE432071T1 (xx)
AU (2) AU2316202A (xx)
BR (1) BR0115527A (xx)
CA (1) CA2457925C (xx)
DE (1) DE60138834D1 (xx)
ES (1) ES2326159T3 (xx)
HK (1) HK1073793A1 (xx)
MX (1) MXPA03004427A (xx)
NO (1) NO20006008L (xx)
NZ (1) NZ525889A (xx)
RU (1) RU2259823C2 (xx)
WO (1) WO2002043728A1 (xx)
ZA (1) ZA200303668B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
AU2003278602C1 (en) 2002-06-20 2010-08-12 Pronova Biopharma Norge As Sulfur-containing phospholipid derivatives
AU2005209331A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
JP2008506774A (ja) * 2004-07-19 2008-03-06 ティア メディカ アクスイェ セルスカプ タンパク質材料と非酸化性脂肪酸体を含む組成物
EP2120916A4 (en) * 2007-02-05 2010-07-28 Children Youth And Women S Hea MODULATORS FOR THE PROLIFERATION OF T CELLS DEPENDENT OF ANTIGEN
DE102011050519A1 (de) * 2011-05-20 2012-11-22 Universität Rostock Alkylschwefelalkansäurederivate und ihre pharmazeutisch verträglichen Salze zur Behandlung chronisch entzündlicher Erkrankungen
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
CA2904827C (en) 2013-03-11 2020-10-27 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
JP7312184B2 (ja) 2017-10-23 2023-07-20 エピトラッカー インコーポレイテッド 脂肪酸アナログおよび代謝症候群に関連する症状の処置におけるそれらの使用
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56164120A (en) * 1980-05-22 1981-12-17 Chisso Corp Antitumor agent
FR2631339B1 (fr) * 1988-05-10 1990-11-16 Cird Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique
DE4120917A1 (de) 1991-06-25 1993-01-07 Basf Ag Ester von fettsaeuren mit aminoalkoholen zur verwendung bei der bekaempfung von krankheiten
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
WO1996011908A1 (en) * 1994-10-13 1996-04-25 Peptide Technology Limited Modified polyunsaturated fatty acids
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
JP2000508645A (ja) * 1996-04-12 2000-07-11 ペプテック リミテッド ポリ不飽和脂肪酸を使用する免疫病の治療方法
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds

Also Published As

Publication number Publication date
CN1633284A (zh) 2005-06-29
US20120101161A1 (en) 2012-04-26
RU2259823C2 (ru) 2005-09-10
CN1296039C (zh) 2007-01-24
US8088825B2 (en) 2012-01-03
ZA200303668B (en) 2004-01-30
EP1351672A1 (en) 2003-10-15
KR20030055322A (ko) 2003-07-02
ES2326159T3 (es) 2009-10-02
CA2457925C (en) 2013-03-26
AU2002223162B2 (en) 2006-11-30
EP1351672B1 (en) 2009-05-27
DE60138834D1 (de) 2009-07-09
AU2316202A (en) 2002-06-11
JP4368579B2 (ja) 2009-11-18
NO20006008D0 (no) 2000-11-28
US20050165103A1 (en) 2005-07-28
MXPA03004427A (es) 2004-05-04
JP2004514693A (ja) 2004-05-20
HK1073793A1 (en) 2005-10-21
NZ525889A (en) 2004-10-29
CA2457925A1 (en) 2002-06-06
KR100905335B1 (ko) 2009-07-01
ATE432071T1 (de) 2009-06-15
BR0115527A (pt) 2003-09-23
WO2002043728A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
HK1073793A1 (en) Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
EA200100103A1 (ru) Ингибиторы адгезии клеток
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
SG158733A1 (en) Cell adhesion inhibitors
DE69625332D1 (de) Zelle adhäsion hemmenden verbindungen
CY1108706T1 (el) Ανοσορυθμιστης
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
EP1983000A3 (en) Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ID29158A (id) Monoester probukol untuk pengobatan penyakit kardiovaskular dan peradangan
BR0210855A (pt) Método de fabricação de formulações de liberação prolongada
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
BR0008059A (pt) Composições de valdecoxib
EE9900428A (et) Köhavastased ravimkoostised
NO20034139D0 (no) Faste oralt-dispersible farmasöytiske formuleringer
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
SE9603725D0 (sv) New teatment
AU5462601A (en) Methods for treatment of diseases associated with inflammation under non-ischemic conditions
MX2023012110A (es) Compuestos de tienopirrol.
DK1342410T3 (da) Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
RU2007138266A (ru) Комбинация ингибитора стероидсульфатазы и аскомицина
PT1392672E (pt) Clorometilacao de tiofeno
NO20032054L (no) Fettsyreanaloger for behandling av inflammatoriske lidelser og autoimmune forstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application